Celularity (CELUW) Non-Current Assets (2018 - 2025)
Celularity (CELUW) reported Non-Current Assets of $95.0 million for Q4 2025, down 15.26% year-over-year from $112.1 million in Q4 2024, and down 8.33% quarter-over-quarter from $103.6 million in Q3 2025.
Celularity (CELUW) Non-Current Assets (2018 - 2025) Analysis & Trends
Celularity (CELUW) has 8 years of Non-Current Assets data on file, last reported at $95.0 million in Q4 2025.
- Non-Current Assets for Q4 2025 came in at $95.0 million, down 15.26% year-over-year; the trailing twelve-month figure through Dec 2025 was $408.5 million (down 12.19% YoY), and the FY2025 annual result was $95.0 million, down 15.26% from the prior year.
- Non-Current Assets slipped to $95.0 million in Q4 2025 per CELUW's latest filing, from $103.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $374.0 million in Q3 2022 and troughed at $95.0 million in Q4 2025.
- A 5-year average of $214.5 million and a median of $134.5 million in 2021 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets jumped 175.7% in 2022, then slumped 66.24% in 2023.
- A 5-year view of Non-Current Assets shows it stood at $355.0 million in 2021, then gained by 3.53% to $367.6 million in 2022, then sank by 66.24% to $124.1 million in 2023, then decreased by 9.65% to $112.1 million in 2024, then retreated by 15.26% to $95.0 million in 2025.
- Business Quant data shows CELUW's Non-Current Assets at $95.0 million in Q4 2025, $103.6 million in Q3 2025, and $103.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Celularity | - | - | -3.27 Mn | 95.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 95.01 Mn |
| Sep 30, 2025 | 103.64 Mn |
| Jun 30, 2025 | 103.02 Mn |
| Mar 31, 2025 | 106.80 Mn |
| Dec 31, 2024 | 112.12 Mn |
| Sep 30, 2024 | 114.34 Mn |
| Jun 30, 2024 | 117.76 Mn |
| Mar 31, 2024 | 120.96 Mn |
| Dec 31, 2023 | 124.10 Mn |
| Sep 30, 2023 | 140.69 Mn |
| Jun 30, 2023 | 228.38 Mn |
| Mar 31, 2023 | 337.41 Mn |
| Dec 31, 2022 | 367.56 Mn |
| Sep 30, 2022 | 374.02 Mn |
| Jun 30, 2022 | 353.88 Mn |
| Mar 31, 2022 | 358.46 Mn |
| Dec 31, 2021 | 355.03 Mn |
| Sep 30, 2021 | 357.01 Mn |
| Jun 30, 2021 | 128.36 Mn |
| Mar 31, 2021 | 291.83 Mn |